Literature DB >> 18192916

Albumin mRNA in plasma predicts post-transplant recurrence of patients with hepatocellular carcinoma.

Siu Tim Cheung1, Sheung Tat Fan, Yuk Ting Lee, Jeremy P Chow, Irene O Ng, Daniel Y Fong, Chung Mau Lo.   

Abstract

BACKGROUND: Currently, hepatocellular carcinoma (HCC) patients are selected for liver transplantation based on radiological assessment (size and number of tumor nodules) and/or pathological features (tumor grade and vascular invasion). The former criteria have limited power on prognosis, whereas the latter do not provide complete information until explant is available.
METHODS: This study aims to investigate whether quantitative measurement of plasma mRNA derived from cancer can provide preoperative prognostic information. Preoperative plasma samples obtained from 72 HCC patients who had undergone liver transplantation were studied. The patients were selected for liver transplantation largely based on the Milan criteria before 2002 and UCSF criteria after 2002. Real-time quantitative reverse transcriptase polymerase chain reaction with Taqman system was used to measure the albumin mRNA levels in plasma.
RESULTS: Fifteen patients (21%) had HCC recurrences. Patients with a high plasma albumin mRNA level (>14.6) had a significantly higher recurrence rate (log-rank test, P=0.001). High plasma albumin mRNA level predicted 2-year HCC recurrence with sensitivity and specificity of 73% and 70%, respectively. By multivariate analysis, plasma albumin mRNA level (adjusted hazard ratio=5.9, P=0.002) and vascular invasion (adjusted hazard ratio=6.0, P=0.001) were the only independent risk factors for prediction of HCC recurrence.
CONCLUSIONS: Plasma albumin mRNA quantification predicts posttransplant HCC recurrence. It may supplement the current selection criteria of HCC patients for liver transplantation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18192916     DOI: 10.1097/01.tp.0000298003.88530.11

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  15 in total

1.  Chemerin reverses the malignant phenotype and induces differentiation of human hepatoma SMMC7721 cells.

Authors:  Ming Li; Pengcheng Sun; Kaikai Dong; Ye Xin; Aslee TaiLulu; Qinyu Li; Jing Sun; Min Peng; Ping Shi
Journal:  Arch Pharm Res       Date:  2021-01-27       Impact factor: 4.946

2.  Glypican-3 expression and its relationship with recurrence of HCC after liver transplantation.

Authors:  Yu-Liang Wang; Zhi-Jun Zhu; Da-Hong Teng; Zhi Yao; Wei Gao; Zhong-Yang Shen
Journal:  World J Gastroenterol       Date:  2012-05-21       Impact factor: 5.742

3.  Biomarkers for hepatocellular carcinoma.

Authors:  Tara Behne; M Sitki Copur
Journal:  Int J Hepatol       Date:  2012-05-10

4.  Clinical values of AFP, GPC3 mRNA in peripheral blood for prediction of hepatocellular carcinoma recurrence following OLT: AFP, GPC3 mRNA for prediction of HCC.

Authors:  Yuliang Wang; Zhongyang Shen; Zhijun Zhu; Ruifa Han; Mingsheng Huai
Journal:  Hepat Mon       Date:  2011-03       Impact factor: 0.660

5.  Bayesian penalized cumulative logit model for high-dimensional data with an ordinal response.

Authors:  Yiran Zhang; Kellie J Archer
Journal:  Stat Med       Date:  2020-12-18       Impact factor: 2.497

Review 6.  Circulating RNA molecules as biomarkers in liver disease.

Authors:  Liviu S Enache; Elena L Enache; Christophe Ramière; Olivier Diaz; Ligia Bancu; Anca Sin; Patrice André
Journal:  Int J Mol Sci       Date:  2014-09-30       Impact factor: 5.923

Review 7.  Tissue- and Serum-Associated Biomarkers of Hepatocellular Carcinoma.

Authors:  Ranjit Chauhan; Nivedita Lahiri
Journal:  Biomark Cancer       Date:  2016-07-04

8.  Expansion of the Milan criteria without any sacrifice: combination of the Hangzhou criteria with the pre-transplant platelet-to-lymphocyte ratio.

Authors:  Weiliang Xia; Qinghong Ke; Hua Guo; Weilin Wang; Min Zhang; Yan Shen; Jian Wu; Xiao Xu; Sheng Yan; Jun Yu; Mangli Zhang; Shusen Zheng
Journal:  BMC Cancer       Date:  2017-01-05       Impact factor: 4.430

9.  Two-transcript gene expression classifiers in the diagnosis and prognosis of human diseases.

Authors:  Lucas B Edelman; Giuseppe Toia; Donald Geman; Wei Zhang; Nathan D Price
Journal:  BMC Genomics       Date:  2009-12-05       Impact factor: 3.969

10.  Circulating nucleic acids in plasma and serum: diagnosis and prognosis in cancer.

Authors:  Peter Brian Gahan
Journal:  EPMA J       Date:  2010-06-09       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.